Search
Momelotinib
go.drugbank.com/drugs/DB11763ApprovedInvestigationalMomelotinib works to block the JAK-signal transducer and activator of transcription (STAT) signalling pathway, which is aberrant in MF.[A261561, A261566, A261571] … [A261566] First approved by the FDA on September 15, 2023,[L48206] momelotinib is used to treat myelofibrosis.
Synonyms: N-(CYANOMETHYL)-4-(2-(4-MORPHOLINOANILINO)PYRIMIDIN-4-YL)BENZAMIDEPhentolamine
go.drugbank.com/drugs/DB00692ApprovedInvestigationalWhile initially introduced to the market for the treatment of hypertension, this clinical use was halted due to cardiovascular and gastrointestinal adverse effects with the prolonged use of large oral … Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation.
Synonyms: 2-(N-(m-hydroxyphenyl)-p-toluidinomethyl)imidazolineCategories: Non-selective Alfa-adrenergic Blocking AgentsGlycerol phenylbutyrate
go.drugbank.com/drugs/DB08909ApprovedInvestigationalGlycerol phenylbutyrate is a nitrogen-binding agent. Chemically, it is a triglyceride in which three molecules of phenylbutyrate are linked to a glycerol backbone. FDA approved on February 1, 2013.
Belladonna
go.drugbank.com/drugs/DB13913Approved[DB00572] is a non-selective muscarinic antagonist that is mainly used as an adjunct for anaesthesia. … Belladonna, also known as atropa belladonna or deadly nightshade, is a perennial herbaceous plant in the nightshade family _Solanaceae_.
Teprotumumab
go.drugbank.com/drugs/DB06343ApprovedInvestigationalapproved by the FDA in January 2020 for the treatment of TED. … multiple invasive surgeries - teprotumumab is the first drug ever approved for the treatment of TED and therefore represents a significant step forward in the treatment this disease.
Synonyms: Immunoglobulin G1, anti-(human insulin-like growth factor I receptor) (human monoclonal heavy chain), disulfide with human monoclonal light chain, dimerLazertinib
go.drugbank.com/drugs/DB16216ApprovedInvestigational[A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations. … [A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184]
Synonyms: N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)PYRIMIDIN-2-YL)AMINO)-4-METHOXY-2-MORPHOLINOPHENYL)ACRYLAMIDE, 2-PROPENAMIDE, N-(5-((4-(4-((DIMETHYLAMINO)METHYL)-3-PHENYL-1H-PYRAZOL-1-YL)-2-PYRIMIDINYL)AMINO)-4-METHOXY-2-(4-MORPHOLINYL)PHENYL)-Mirdametinib
go.drugbank.com/drugs/DB07101ApprovedInvestigationalMirdametinib is a mitogen-activated protein kinase (MAP2K, MEK, MAPKK) inhibitor. On February 11, 2025, mirdametinib was approved by the FDA for the treatment of neurofibromatosis type 1 (NF1). … [L52485] NF1 is an autosomal-dominant genetic condition caused by loss-of-function variants in the _NF1_ tumour suppressor gene,[A265065,A265070] leading to neurofibromin dysfunction and aberrant activation
Synonyms: (-)-N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDE, N-(((R)-2,3-DIHYDROXYPROPYL)OXY)-3,4-DIFLUORO-2-((2-FLUORO-4-IODOPHENYL)AMINO)BENZAMIDEAlglucerase
go.drugbank.com/drugs/DB00088ApprovedWithdrawnHuman Beta-glucocerebrosidase or Beta-D-glucosyl-N-acylsphingosine glucohydrolase E.C. 3.2.1.45. 497 residue protein with N-linked carbohydrates, MW=59.3 kD. … Alglucerase was first approved by the FDA in 1991;[A254816] however, it was later discontinued from the market.
Thonzonium
go.drugbank.com/drugs/DB09552ApprovedIt is widely used as an additive to in ear and nasal drops to enhance dispersion and penetration of cellular debris and exudate, thereby promoting tissue contact of the administered medication. … A common pharmaceutical formulation of thonzonium bromide is cortisporin-TC ear drops. It is also reported that thonzonium also confers an antifungal property and antiresorptive effect on bone.
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnEnoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. … It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries.
Categories: Compounds used in a research, industrial, or household setting